The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...
The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...